#ASCO18: AbbVie convinces one top analyst that its $6B ‘megablockbuster’ Rova-T is worthless

#ASCO18: AbbVie convinces one top analyst that its $6B ‘megablockbuster’ Rova-T is worthless

Submitted by admin on June 5, 2018 - 12:09pm
Source: 
Endpoints
News Tags: 
AbbVie
Rova-T
ASCO 2018
antibody-drug conjugate
Headline: 
#ASCO18: AbbVie convinces one top analyst that its $6B ‘megablockbuster’ Rova-T is worthless
snippet: 

AbbVie $ABBV has managed to convince at least one prominent analyst that Rova-T is absolutely worthless, as the company’s vision of a $5 billion earner gradually dissolves.

Do Not Allow Advertisers to Use My Personal information